Reported results
- Immix reported $340.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026.
- Total operating expenses were $15.9 million for the three months ended September 30, 2026.
- Net loss for the period was $13.9 million for the three months ended September 30, 2026.
- Research and Development costs were $5.5 million for the three months ended September 30, 2026.
- General and Administrative costs were $10.4 million for the three months ended September 30, 2026.
Guidance
- Cash, cash equivalents, and marketable securities as of September 30, 2026 are expected to provide operating runway into mid-2028.
- Immix plans for its BLA submission in mid-2027 and NEXICART-3 front line trial initiation in the first half of 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
